LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study

Journal article

Open access

Peer reviewed

R.L. Coleman, D. Lorusso, C. Gennigens, A. González-Martín, L. Randall, D. Cibula, B. Lund, L. Woelber, S. Pignata, F. Forget, …

Annals of oncology, Vol.31, pp.S1162-S1163

09/2020

Files and links (1)

url

https://doi.org/10.1016/j.annonc.2020.08.2262View

Published (Version of record) Open

1 Record Views

Title: LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study
Creators: R.L. Coleman - Medical Oncology, US Oncology, The Woodlands, Houston, TX, USA
D. Lorusso - Agostino Gemelli University Polyclinic
C. Gennigens - Centre Hospitalier Universitaire de Liège
A. González-Martín - Clinica Universidad de Navarra
L. Randall - Virginia Commonwealth University Medical Center
D. Cibula - Charles University
B. Lund - Aalborg University Hospital
L. Woelber - University Medical Center Hamburg-Eppendorf
S. Pignata - Fondazione IRCCS Istituto Nazionale dei Tumori
F. Forget - Medical Oncology, Centre Hospitalier de l'Ardenne, Libramont, Belgium
A. Redondo - Hospital Universitario La Paz
R. Rangwala - Genmab
S.D. Vindeløv - Genmab
M. Chen - Genmab
J.R. Harris - Genmab
L. Nicacio - Seagen
M.S.L. Teng - Seagen
M. Smith - Medical Oncology, Genmab US, Inc., Princeton, NJ, USA
B.J. Monk - University of Arizona
I.B. Vergote - KU Leuven
Publication Details: Annals of oncology, Vol.31, pp.S1162-S1163
Publisher: Elsevier Ltd
Identifiers: 991005968793302656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article